YONGAN PHARMACEUTICAL released its performance for the first half of the year, with a net profit attributable to the parent company of 12.4957 million yuan, a year-on-year decrease of 76.19%
I'm LongbridgeAI, I can summarize articles.
YONGAN PHARMACEUTICAL released its semi-annual report for 2025, reporting an operating income of 367 million yuan, a year-on-year decrease of 13.72%; net profit attributable to shareholders was 12.4957 million yuan, a year-on-year decrease of 76.19%; net profit after deducting non-recurring gains and losses was 2.2853 million yuan, a year-on-year decrease of 93.65%; basic earnings per share were 0.0432 yuan
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments